FDMT vs RUN · rev $37.0K vs P/E 6.0, rev $2.04B
4D Molecular Therapeutics Inc (FDMT) versus Sunrun Inc (RUN) — a side-by-side from cached financials, not a winner call.
4D Molecular Therapeutics Inc (FDMT) is a biotechnology company listed on US.
Sunrun Inc (RUN) is a solar company listed on NASDAQ.
Latest reported FDMT revenue for 2024-12-31 was $37.0K. Net income was -$160.9M. Revenue was down 99.8% from 2023-12-31 to 2024-12-31. FDMT currently screens at market cap $518.1M.
Latest reported RUN revenue for 2024-12-31 was $2.04B. Net income was -$4.36B. Revenue was down 9.8% from 2023-12-31 to 2024-12-31. RUN currently screens at market cap $3.05B and trailing P/E 6.0.
FDMT currently screens at market cap $518.1M. RUN currently screens at market cap $3.05B and trailing P/E 6.0.
Not investment advice. Open the FDMT and RUN stock pages for the full models.
Not investment advice.